Should Graf IIc Hips be Treated for 12 Weeks
NCT03275805
Recruiting
Children who are diagnosed with Developmental Hip Dysplasia (DDH) are often categorized depending on the severity of their hip malformation. Regardless of the severity, the accepted form of treatment is the Pavlik Harness. Unfortunately, there is no specific recommended treatment regarding length of Pavlik Harness treatment for patients with DDH who have who have been categorized with stable Graf type IIc hips. The investigators will aim to answer this question with a randomized controlled trial... Read More
Gender:
ALL
Ages:
Between 0 weeks and 18 weeks
Trial Updated:
04/02/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Developmental Dysplasia of Hip
Register for Updates
Neoadjuvant Chemoradiation for Resectable Glioblastoma
NCT04209790
Recruiting
Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the predominant mode of failure in these patients leading to poor outcomes. This Phase II study design would be used to proceed with the study treatment after meeting pre-specified events in the initial phase, with goal being to determine whether the new treatment paradigm is suf... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/02/2025
Locations: Geisinger Medical Center, Danville, Pennsylvania +1 locations
Conditions: Glioblastoma, Surgery, High Grade Glioma
Register for Updates
Telehealth and Memory Study
NCT04586530
Recruiting
The overall purpose of this trial is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction among (female or male) breast cancer survivors. This is a multi-center, multi-clinician randomized control trial (MAAT vs. supportive therapy attention control condition). This trial will also evaluate a sub-sample of survivors pre-and post treatment with functional magnetic resonance imag... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Indiana University, Indianapolis, Indiana +1 locations
Conditions: Chemotherapy-related Cognitive Dysfunction
Register for Updates
TReatment for ImmUne Mediated PathopHysiology
NCT04862221
Recruiting
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
04/02/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +21 locations
Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Register for Updates
Breaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes
NCT05041491
Recruiting
Newly released guidelines recommend increased physical activity (PA) and reduced sedentary behaviors (SB) to improve glycemia and prevent the onset and progression of type 2 diabetes (T2D). Typically, 30-60 min bouts of PA are advocated per day. Although this approach increases PA, it does not decrease the length of the sedentary periods through the day. This is important because recent epidemiological data suggest that frequently interrupting sedentary time improves glucose control even in peop... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/02/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Pre-diabetes
Register for Updates
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973
Recruiting
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethni... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: City of Hope, Duarte, California +45 locations
Conditions: Amyloidosis
Register for Updates
A Study of Daratumumab
NCT05438043
Recruiting
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/02/2025
Locations: University of Miami Sylvester Cancer Center, Miami, Florida +75 locations
Conditions: Multiple Myeloma
Register for Updates
δ in Dementia Clinical Trials
NCT05592678
Recruiting
The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are: * Can an intervention's outcome be better assessed by a latent variable ("δ") integrating cognitive performance with functional status? * Can latent biomarkers of δ guide the selection of an intervention that will modulate dementia severity? * Can a latent variable, derived from information collected remotely fro... Read More
Gender:
ALL
Ages:
Between 65 years and 100 years
Trial Updated:
04/02/2025
Locations: Univeristy of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas
Conditions: Alzheimer's Disease (AD), Dementia, Cognitive Decline, Mild Cognitivie Impairment (MCI)
Register for Updates
AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Boys With DMD
NCT05683379
Recruiting
This is an observational screening study to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in participants with Duchenne muscular dystrophy (DMD).
Gender:
MALE
Ages:
Between 0 years and 11 years
Trial Updated:
04/02/2025
Locations: Rare Disease Research, Atlanta, Georgia
Conditions: Duchenne Muscular Dystrophy
Register for Updates
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
NCT05787561
Recruiting
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Mesonephric Gynecologic Cancer
Register for Updates
Intervention for Virologic Suppression in Youth
NCT05877729
Recruiting
The goal of this randomized clinical trial is to test the effect of a technology-based intervention with an Adaptive Treatment Strategy (ATS) among youth living with HIV (YLWH) (18-29 years old). This piloted and protocolized intervention combines: (1) brief weekly sessions with a counselor via a video-chat platform (video-counseling) to discuss mental health (MH), substance use (SU), HIV care engagement, and other barriers to care; and (2) a mobile health application (app) to address barriers s... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
04/02/2025
Locations: Division of Prevention Science, Center for AIDS Prevention Studies (CAPS), San Francisco, California
Conditions: HIV/AIDS, Young Adult, Mobile Health, Mental Health Issue, Substance Use
Register for Updates
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
NCT06071624
Recruiting
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory CMML. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Chronic Myelomonocytic Leukemia
Register for Updates